A review of the metabolism and pharmacokinetics of paroxetine in man

@article{Kaye1989ARO,
  title={A review of the metabolism and pharmacokinetics of paroxetine in man},
  author={C. M. Kaye and Rebecca Ellen Haddock and P. F. Langley and Graham Mellows and T. C. G. Tasker and B. D. Zussman and W. H. Greb},
  journal={Acta Psychiatrica Scandinavica},
  year={1989},
  volume={80}
}
Paroxetine is well absorbed from the gastrointestinal tract, and appears to undergo first‐pass metabolism which is partially saturable. Consistent with its lipophilic amine character, paroxetine is extensively distributed into tissues. Its plasma protein binding at therapeutically relevant concentrations is about 95%. Paroxetine is eliminated by metabolism involving oxidation, methylation, and conjugation. All of these factors lead to wide interindividual variation in the pharmacokinetics of… 
Pharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CR.
  • C. DeVane
  • Medicine, Psychology
    Psychopharmacology bulletin
  • 2003
TLDR
Considerations of the pharmacokinetic properties of paroxetine support a rationale for the development of new dosage forms that maintain the efficacy yet improve the tolerability profile of the selective serotonin reuptake inhibitors.
Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics
TLDR
It was concluded that inhibition of CYP2D6 by paroxetine markedly affected atomxetine disposition, resulting in pharmacokinetics similar to poor metabolizers of CYp2D 6 substrates.
Pharmacokinetic Optimisation of Therapy with Newer Antidepressants
  • P. Goodnick
  • Medicine, Biology
    Clinical pharmacokinetics
  • 1994
TLDR
The antidepressants best suited for pharmacokinetic optimisation of therapy are the following: desipramine, sertraline, fluvoxamine, citalopram and amfebutamone, which stands out as having the best effects on behaviour among all antidepressants.
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects
TLDR
It is demonstrated that the metabolism of paroxetine after a single oral dose was inhibited by terbinafine, suggesting that inhibition of CYP2D6 activity may lead to a change in the pharmacokinetics of paroxin, however, further study is required to confirm this phenomenon at steady state.
Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction.
TLDR
It is shown that paroxetine abolishes the stereoselective metabolism of metoprolol due to a stereoselectedive inhibition of the O-demethylation toward (R)-metoproll.
Evaluation of Hepatic Disposition of Paroxetine Using Sandwich-Cultured Rat and Human Hepatocytes
TLDR
The usefulness of sandwich-cultured hepatocytes (SCH) to evaluate in vivo species differences of the hepatic disposition of paroxetine between rats and humans was examined and M1-glucuronide was demonstrated to be a multidrug resistance-associated protein 2 substrate in both species.
Paroxetine: pharmacokinetic and antidepressant effect in the elderly
TLDR
Steady‐state, pre‐dose plasma levels of paroxetine showed considerable variability, and the median steady‐state concentration was higher in elderly patients compared with data from a previous study in young volunteers, and elimination half‐lives also showed variability between these elderly patients.
DMD049817 735..743
TLDR
The metabolite profile of [H]paroxetine in SCH was similar to that in hepatocytes in suspension, and the in vitro metabolite profiles were similar to the published in vivo metabolic pathways for both species.
SSRI differentiation: Pharmacology and pharmacokinetics
  • B. Leonard
  • Biology, Medicine
    Human psychopharmacology
  • 1995
TLDR
Differences in potency at inhibiting serotonin reuptake and the suitability of individual SSRIs in special patient groups are apparent and it is worthwhile to be made aware of possible interactions between drugs that act as inhibitors or substrates of the hepatic cytochrome P450 system.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Paroxetine: pharmacokinetics, tolerance and depletion of blood 5-HT in man.
TLDR
The pharmacokinetic studies revealed a dose dependent systemic availability, a rather slow elimination, a good fit to one compartment open model, and an almost complete metabolism of the substance.
The pharmacokinetics of paroxetine in patients with liver cirrhosis
Paroxetine is efficiently absorbed from the gastrointestinal tract. The drug appears to undergo oxidative first-pass metabolism, which is capacity limited and gives rise to non-linear
An overview of the animal pharmacology of paroxetine
  • A. M. Johnson
  • Biology, Psychology
    Acta psychiatrica Scandinavica. Supplementum
  • 1989
TLDR
It is concluded that paroxetine should be an effective antidepressant with a reduced propensity to induce the adverse events that are characteristic of the tricyclic class of antidepressants.
Paroxetine: pharmacokinetic and antidepressant effect in the elderly
TLDR
Steady‐state, pre‐dose plasma levels of paroxetine showed considerable variability, and the median steady‐state concentration was higher in elderly patients compared with data from a previous study in young volunteers, and elimination half‐lives also showed variability between these elderly patients.
Paroxetine plasma levels: lack of correlation with efficacy or adverse events
TLDR
A retrospective analysis of the available data on the relationship between plasma concentrations of paroxetine and efficacy and adverse events is described.
The pharmacokinetics of paroxetine in elderly depressed patients
  • K. Ghose
  • Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1989
TLDR
Steady-state plasma concentradons are usually reached within 10-14 days of commencing dosing with paroxetine in this population of elderly depressed patients, and the elimination $asma half-life shows wide variability between subjects, but is generally about one day.
The pharmacokinetics of paroxetine in renal impairment
TLDR
Neither the terminal phase rate constant (A,) nor the AUC, correlated well with creatinine clearance, but mean maximum plasma concentrations increased steadily with decreasing renal function, but because of wide inter-subject variability this was not statistically significant.
Absorption of paroxetine under various dietary conditions and following antacid intake
TLDR
The aim of this group of studies was to establish whether the systemic availability of paroxetine a lipophilic amine administered as the hydrochloride salt could be influenced by administration with or without food and whether the nature of the food is important.
The pharmacokinetics of paroxetine in the elderly
TLDR
The results generated in an investigation of the oral pharmacokinetics of paroxetine in healthy elderly subjects and healthy elderly Subjects and healthy young adults after a single 20mg dose and after once-daily dosing with 20mg for 15 consecutive days are presented.
Paroxetine: lack of effect on hepatic drug metabolizing enzymes
TLDR
The ability of paroxetine to modify the activity of drug metabolizing enzymes has been studied directly in rats at the relatively high oral dose level of SOmglkg, and indirectly in healthy subjects at a dose level likely to be used in therapy.
...
...